Erlotinib 100mg qd Versus Gefitinib 250mg qd for EGFR Mutant Nsclc (NSCLC EGFR TKI)
|ClinicalTrials.gov Identifier: NCT01955421|
Recruitment Status : Unknown
Verified July 2015 by Li Zhang, Sun Yat-sen University.
Recruitment status was: Recruiting
First Posted : October 7, 2013
Last Update Posted : July 3, 2015
|Condition or disease||Intervention/treatment||Phase|
|Advanced Stage Non Small Cell Lung Cancer||Drug: Erlotinib 100mg qd Drug: Gefitinib 250mg qd||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||224 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Randomized, Open-label Phase II Trial of Erlotinib 100mg Daily Versus Gefitinib 250mg Daily in Patients With Advanced Non-small Cell Lung Cancer Who Harbor EGFR Mutations.|
|Study Start Date :||July 2013|
|Estimated Primary Completion Date :||June 2016|
Patients will be randomized to buy and receive erlotinib 100mg qd.
|Drug: Erlotinib 100mg qd|
Patients will be randomized to buy and receive gefitinib 250mg qd.
|Drug: Gefitinib 250mg qd|
- disease control rate [ Time Frame: 2 years ]
- progression free survival [ Time Frame: 2 years ]
- adverse events [ Time Frame: 2 years ]rash, diarrhea, ILD, etc.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01955421
|Department of Medical Oncology, Cancer Center of Sun Yat-Sen University||Recruiting|
|Guangzhou, Guangdong, China, 510060|
|Contact: Wenhua Liang, MD 8613710249454 firstname.lastname@example.org|
|Principal Investigator: Li Zhang, MD|
|Sub-Investigator: Wenhua Liang, MD|